{"entity":{"id":"idea-bio2-transferrin-shuttle-adc","kind":"idea","name":"Use the brain's own transport door to carry antibody drugs across","aka":[],"tldr":"The brain imports iron through the transferrin receptor. Antibody shuttle domains that bind that receptor raise brain exposure roughly ten to fifty-fold in primates and are already used in clinical Alzheimer's antibodies; the same engineering could carry antibody-drug conjugates or T-cell engagers to brain metastases.","summary":"Transferrin receptor-binding shuttle domains raise brain exposure of antibodies roughly ten to fifty-fold in primates and are being used in clinical Alzheimer's antibodies and enzyme replacement therapies. Applying the same engineering to antibody-drug conjugates or T-cell engagers directed at brain metastasis antigens is a well-defined, if demanding, protein engineering task with a real precedent from another disease area.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (The brain: barrier and sanctuary): Stupp et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma (NEJM 2005)","url":"https://doi.org/10.1056/NEJMoa043330"}],"tags":[],"related":[],"cancers":["breast-her2-positive","nsclc"],"sections":[],"technologies":["adc","bispecific-antibody","t-cell-engager"],"targets":["her2","her3","trop2"],"drugs":["trastuzumab-deruxtecan","tucatinib"],"companies":[],"institutions":[],"pathways":[],"terms":["blood-brain-barrier","her2-brain-metastases"],"trials":[],"people":[],"bottlenecks":["b-brain-delivery","b-undruggable-targets"],"keyPapers":["paper-slamon-her2-breast-ovarian-science-1989","paper-yarden-sliwkowski-erbb-network-nrmcb-2001"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"A shuttle-enabled HER2 antibody-drug conjugate achieves at least tenfold higher brain concentration than the parent molecule and produces intracranial responses in patients whose brain metastases progress on standard ADCs.","rationale":"Shuttle engineering has moved from concept to clinical validation in neurology, so the platform risk is now largely retired. Brain metastases with retained antigen expression are a large, poorly served population where the only obstacle is delivery.","test":"Measure primate brain pharmacokinetics of shuttle versus parent conjugate, then run a phase 1 in HER2-positive brain metastasis with intracranial response and, where feasible, cerebrospinal fluid or resected-tissue drug measurement.","maturity":"preclinical-evidence","actor":"industry","cost":"medium","horizonYears":8},"route":"/ideas/idea-bio2-transferrin-shuttle-adc/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"her3","kind":"target","name":"HER3","route":"/targets/her3/"},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"},{"id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/"}],"term":[{"id":"blood-brain-barrier","kind":"term","name":"Blood-brain barrier (BBB)","route":"/terms/blood-brain-barrier/"},{"id":"her2-brain-metastases","kind":"term","name":"HER2-positive brain metastases","route":"/terms/her2-brain-metastases/"}],"bottleneck":[{"id":"b-brain-delivery","kind":"bottleneck","name":"The brain: barrier and sanctuary","route":"/bottlenecks/b-brain-delivery/"},{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/"}],"paper":[{"id":"paper-slamon-her2-breast-ovarian-science-1989","kind":"paper","name":"Slamon 1989: HER2/neu in human breast and ovarian cancer","route":"/key-papers/paper-slamon-her2-breast-ovarian-science-1989/"},{"id":"paper-yarden-sliwkowski-erbb-network-nrmcb-2001","kind":"paper","name":"Yarden and Sliwkowski 2001: untangling the ErbB signalling network","route":"/key-papers/paper-yarden-sliwkowski-erbb-network-nrmcb-2001/"}]}}